Bristol-Myers Squibb has announced positive results for the fourth quarter 2010, with net sales of $5.1bn despite a 1.5% negative effect due to US healthcare reforms.

The company’s net US sales increased by 5% to $3.3bn, whereas international net sales decreased 5%, including foreign exchange impact, to $1.8bn.

Despite the increase in sales, R& expenses decreased by 9% to $1bn.

Bristol-Myers Squibb anticipates stronger results in 2011, with several pipeline events set to effect the company’s performance.